Search Within

Raajit Kumar Rampal

Formats
  1. Meeting Abstract (191)
  2. Journal Article (123)
  3. Review (21)
  4. Research Letter (10)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (351)
  2. Center for Hematologic Malignancies (351)
  3. Department of Medicine (351)
  4. Hematologic Malignancies, Division of (351)
  5. GSK Faculty (135)
  6. Executive Committee, Center for Hematologic Malignancies (131)

More Groups

People
  1. Ross Levine (87)
  2. Omar Abdel-Wahab (64)
  3. Martin Tallman (41)
  4. Eli Diamond (34)
  5. Ahmet Dogan (30)
  6. Minal Patel (29)

More People

Years
  1. 2025 (15)
  2. 2024 (35)
  3. 2023 (42)
  4. 2022 (36)
  5. 2021 (36)
  6. 2020 (26)

More Years

Publications
  1. Blood (148)
  2. Journal of Clinical Oncology (18)
  3. Blood Advances (15)
  4. Clinical Lymphoma, Myeloma and Leukemia (15)
  5. Haematologica (13)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (164)
  2. Elsevier Inc. (24)
  3. Nature Publishing Group (22)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (13)
  6. American Association for Cancer Research (12)

More Publishers

Results (351)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, showed durable clinical response and sustained hematological improvement in relapsed/refractory myelofibrosis patients
    Meeting Abstract

    El Chaer, F.; Rein, L. A. M.; Yuda, J.; Shimoda, K.; Takami, A.; Ichii, M.; McCloskey, J.; Scandura, J. M.; Iurlo, A.; Bose, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Non-driver genomic alterations and venous thromboembolism in myeloproliferative neoplasms
    Meeting Abstract

    Ajufo, H.; Leader, A.; Derkach, A.; Chrysafi, P.; Singh, R.; Rampal, R.; Mantha, S.; Zwicker, J. I.
    Blood (2024)

    Fulltext@MSK | Save
  • Hematologic improvement experienced by pacritinib-treated patients with myelofibrosis in real-world clinical settings
    Meeting Abstract

    Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.; Mascarenhas, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • TP53 alterations confer increased risk of leukemic transformation and worse survival as compared to high molecular risk mutations in patients with myeloproliferative neoplasms
    Meeting Abstract

    Handa, S.; Riazat-Kesh, Y. J. R. A.; Butterfield, R. J.; Sivakumar, G.; Venugopal, S.; McGovern, E.; Feld, J.; Tremblay, D.; Elghaity-Beckley, S.; Kremyanskaya, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A multicenter, open-label, phase 1 clinical trial of AJ1-11095 administered as oral monotherapy in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have been failed by a type I JAK2 inhibitor (JAK2i)
    Meeting Abstract

    Mascarenhas, J. O.; Borate, U.; Bose, P.; Byrd, J. C.; Garcia, J. S.; Grunwald, M. R.; Hobbs, G. S.; Hoffman, R.; Kuykendall, A. T.; Mesa, R. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naive patients with myelofibrosis who have a suboptimal response to ruxolitinib
    Meeting Abstract

    Vachhani, P.; Rampal, R.; Bradley, T.; Harrison, C.; Jain, T.; Kuykendall, A. T.; Palandri, F.; Mascarenhas, J. O.; Al-Ali, H. K.; Passamonti, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Trial in progress: An open-label clinical trial of RVU120 as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)
    Meeting Abstract

    Kuklik, R.; Falkowski, A.; Zaroogian, Z.; Mazan, M.; Szymula, A.; Wilkinson, G.; Adamczyk, E.; Woznicki, J.; Micek, M.; Coelho, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-word effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia
    Meeting Abstract

    Rampal, R.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Mascarenhas, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • Early anemia response in patients with myelofibrosis treated with pacritinib in real-word clinical settings
    Meeting Abstract

    Mascarenhas, J. O.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis
    Meeting Abstract

    Mascarenhas, J. O.; Rampal, R.; El Chaer, F.; Gupta, V.; Shimoda, K.; Kiladjian, J. J.; Passamonti, F.; Bose, P.; Scandura, J. M.; Mesa, R.; more...
    Blood (2024)

    Fulltext@MSK | Save